Research Article| Volume 1, ISSUE 3, P547-557, September 1981


  • Carl E. Speicher
    Corresponding author: Department of Pathology, The Ohio State University, 410 W. 10th Avenue, Columbus, Ohio 43210
    Professor, Department of Pathology, The Ohio State University College of Medicine; Director, Clinical Laboratories, Ohio State University Hospitals, Columbus, Ohio
    Search for articles by this author
  • Martha I. Walters
    Assistant Professor, Department of Pathology, The Ohio State University College of Medicine; Director, Therapeutic Drug Monitoring Laboratory, Ohio State University Hospitals, Columbus, Ohio
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.
      Therapeutic monitoring of phenothiazine therapy for psychotic disorders is limited because of an inability to consistently correlate plasma levels with clinical outcome. However, laboratories should have a method available to assist clinicians in determining compliance or in diagnosing toxicity. It is hoped that better methods for measuring these agents in body fluids and tissues will elucidate effective therapeutic monitoring of phenothiazines.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Medical Association Department of Drugs
        AMA Drug Evaluations.
        American Medical Association, Chicago1980
        • Bailey D.N.
        • Guba J.J.
        Gas-chromatographic analysis for chlorpromazine and some of its metabolites in human serum, with use of a nitrogen detector.
        Clin. Chem. 1979; 25: 1211-1215
        • Bergling R.
        • Mjorndal T.
        • Oreland L.
        • et al.
        Plasma levels and clinical effects of thioridazine and thiothixene.
        J. Clin. Pharmacol. 1975; 75: 178-186
        • Casper R.
        • Garver D.L.
        • Dekirmenjian H.
        • et al.
        Phenothiazine levels in plasma and redblood cells.
        Arch. Gen. Psychiatry. 1980; 37: 301-305
        • Curry S.H.
        Pharmacokinetics and psychotropic drugs.
        Psychol. Med. 1978; 8 (editorial): 177-180
        • Feldman V.
        Serious reactions to phenothiazines.
        J. Pediatr. 1976; 76 (letter): 163-164
        • Forrest I.S.
        • Forrest F.M.
        Urine color test for detection of phenothiazine compounds.
        Clin. Chem. 1960; 6: 11-15
        • Goodman A.G.
        • Goodman L.S.
        • Gilman A.
        The Pharmacological Basis of Ther apeutics.
        Macmillan Publishing Co., Inc., New York1980: 391-418
        • Hollister L.E.
        Mental disorders—antipsychotic and antimanic drugs.
        in: Drug Therapy from the New England Journal of Medicine 1972–1974. Massachusetts Medical Society, Boston1976: 62-71
        • Javaid J.I.
        • Dekirmenjian H.
        • Dysken M.
        • et al.
        Measurement of fluphenazine by gas chromatography in human plasma and red blood cells.
        Adv. Biochem. Psychopharmacol. 1980; 24: 585-589
        • Kaye S.
        • Rodriguez Ramos J.R.
        The toxicology of the phenothiazines.
        Bol. Asoc. Med. P. R. 1976; 68: 148-153
        • Kolakowska T.
        • Orr M.
        • Gelder M.
        • et al.
        Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment. A replication study.
        Br. J. Psychiatry. 1979; 135: 352-359
        • May P.R.A.
        • Van Putten T.V.
        Plasma levels of chlorpromazine in schizophrenia.
        Arch. Gen. Psychiatry. 1978; 35: 1081-1087
      1. Physicians’ Desk Reference. Oradell, New Jersey, Medical Economics Company, 1981.

        • Rivera-Calimlim L.
        • Castaneda L.
        • Lasagna L.
        Effect of mode of management on plasma chlorpromazine in psychiatric patients.
        Clin. Pharmacol. Ther. 1973; 14: 978-986
        • Rivera-Calimlim L.
        • Nasrallah H.
        • Strauss J.
        • et al.
        Clinical response and plasma levels: Effect of schedules, and drug interactions on chlorpromazine levels.
        Am. J. Psychiatry. 1976; 133: 646-652
        • Sakalis G.
        • Sudilovsky A.
        • Traficante L.J.
        • et al.
        Clinical response and plasma levels of fluphenazine: Pharmacokinetic and methodologic considerations.
        in: Ayd F.J. Depot Fluphenazines: Twelve Years of Experience. Ayd Medical Communications, Baltimore1978
        • Sakurai Y.
        • Takahashi R.
        • Nakahara T.
        • et al.
        Prediction of response to and actual outcome of chlorpromazine treatment in schizophrenic patients.
        Arch. Gen. Psychiatry. 1980; 37: 1057-1062
        • Speicher C.E.
        Survey of Request Forms and Report Forms in Therapeutic Drug Monitoring and Toxicology.
        Technical Bulletin of The Ohio State University, Columbus, Ohio1980
        • Swett C.
        Adverse reactions to chlorpromazine in medical patients.
        Curr. Ther. Res. 1975; 18: 199-206
        • Tietz N.
        Fundamentals of Clinical Chemistry.
        Edition 2. W.B. Saunders Co., Philadelphia1976: 1146
        • Tune L.E.
        • Creese I.
        • Depaulo R.J.
        • et al.
        Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
        Am. J. Psychiatry. 1980; 137: 187-190
        • Vanderheeren F.A.
        • Theunis D.J.
        Gas-liquid chromatographic determination of perazine, thioridazine and thioridazine metabolites in human plasma.
        J. Chromatogr. 1976; 120: 123-128
        • Van Putten T.V.
        • May P.R.A.
        • Jenden D.J.
        • et al.
        Plasma and saliva levels of chlorpromazine and subjective response.
        Am. J. Psychiatry. 1980; 137: 1241-1242
        • Whyman A.
        Phenothiazine death: An unusual case report.
        J. Nerv. Ment. Dis. 1976; 136: 214-217